NASDAQ:AEMD Aethlon Medical (AEMD) Stock Price, News & Analysis → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free AEMD Stock Alerts $0.45 -0.40 (-47.12%) (As of 11:28 AM ET) Add Compare Share Share Today's Range$0.44▼$0.5450-Day Range$0.85▼$1.7652-Week Range$0.44▼$5.00Volume4.19 million shsAverage Volume302,418 shsMarket Capitalization$1.18 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Aethlon Medical alerts: Email Address Aethlon Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,117.8% Upside$10.00 Price TargetShort InterestBearish3.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.98) to ($5.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAethlon Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAethlon Medical has only been the subject of 1 research reports in the past 90 days.Read more about Aethlon Medical's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.04% of the float of Aethlon Medical has been sold short.Short Interest Ratio / Days to CoverAethlon Medical has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Aethlon Medical has recently increased by 133.89%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAethlon Medical does not currently pay a dividend.Dividend GrowthAethlon Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEMD. Previous Next 2.6 News and Social Media Coverage News SentimentAethlon Medical has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Aethlon Medical this week, compared to 1 article on an average week.Search Interest5 people have searched for AEMD on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aethlon Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Aethlon Medical is held by insiders.Percentage Held by InstitutionsOnly 1.99% of the stock of Aethlon Medical is held by institutions.Read more about Aethlon Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aethlon Medical are expected to decrease in the coming year, from ($4.98) to ($5.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aethlon Medical is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aethlon Medical is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAethlon Medical has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aethlon Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About Aethlon Medical Stock (NASDAQ:AEMD)Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Read More AEMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEMD Stock News HeadlinesMay 15 at 9:15 AM | prnewswire.comAethlon Medical Announces Pricing of $4.7 Million Public OfferingMay 14 at 3:52 AM | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.comMay 11, 2024 | americanbankingnews.comAethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Increase in Short InterestMay 10, 2024 | markets.businessinsider.comAethlon Medical Stock Surges In Pre-market On Positive Hemopurifier Trial ResultsMay 10, 2024 | marketwatch.comAethlon Medical Shares Double After Positive Results from Early Trial of HemopurifierMay 10, 2024 | prnewswire.comAethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient PlasmaMay 6, 2024 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.comMarch 25, 2024 | money.usnews.comAethlon Medical IncMarch 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)March 2, 2024 | investing.comAethlon Medical Inc (AEMD)February 21, 2024 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesFebruary 21, 2024 | markets.businessinsider.comAethlon Inks Materials Transfer Deal For Santersus' NucleoCapture And HemoNucleoCapture DevicesFebruary 21, 2024 | finance.yahoo.comAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesFebruary 21, 2024 | prnewswire.comAethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture DevicesFebruary 18, 2024 | finanznachrichten.deAethlon Medical, Inc.: Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 15, 2024 | finance.yahoo.comAEMD: Focus on Oncology Studies; In Vitro Binding Study Expected to Advance Clinical Trial ActivitiesFebruary 15, 2024 | finance.yahoo.comAethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call TranscriptFebruary 14, 2024 | finance.yahoo.comAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 14, 2024 | prnewswire.comAethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate UpdateFebruary 13, 2024 | msn.comAethlon Medical Q3 2024 Earnings PreviewFebruary 13, 2024 | benzinga.comEarnings Preview: Aethlon MedicalFebruary 7, 2024 | finance.yahoo.comAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024November 18, 2023 | markets.businessinsider.comMaxim Group Keeps Their Hold Rating on Aethlon Medical (AEMD)November 16, 2023 | finance.yahoo.comAEMD: Expect Focus on Oncology Studies; Cost Containment EffortsNovember 16, 2023 | finance.yahoo.comAethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call TranscriptSee More Headlines Receive AEMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today5/15/2024Next Earnings (Estimated)6/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AEMD CUSIPN/A CIK773910 Webwww.aethlonmedical.com Phone(858) 459-7800FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,076.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,030,000.00 Net MarginsN/A Pretax Margin-2,133.97% Return on Equity-106.28% Return on Assets-86.60% Debt Debt-to-Equity RatioN/A Current Ratio3.93 Quick Ratio3.93 Sales & Book Value Annual Sales$570,000.00 Price / Sales3.91 Cash FlowN/A Price / Cash FlowN/A Book Value$6.56 per share Price / Book0.13Miscellaneous Outstanding Shares2,620,000Free Float2,515,000Market Cap$2.23 million OptionableNo Data Beta1.95 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Guy F. Cipriani BS (Eng.) (Age 53)MBA, Chief Operating Officer Comp: $347.5kDr. Steven P. LaRosa M.D. (Age 57)Chief Medical Officer Comp: $430kMr. James B. Frakes M.B.A. (Age 67)Interim CEO, CFO, Secretary & Director Comp: $385kDr. Lee D. Arnold Ph.D. (Age 64)Chief Scientific Officer Key CompetitorsReShape LifesciencesNASDAQ:RSLSDynatronicsNASDAQ:DYNTG Medical InnovationsNASDAQ:GMVDFAssureNASDAQ:IONMQuoin PharmaceuticalsNASDAQ:QNRXView All Competitors AEMD Stock Analysis - Frequently Asked Questions Should I buy or sell Aethlon Medical stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEMD shares. View AEMD analyst ratings or view top-rated stocks. What is Aethlon Medical's stock price target for 2024? 1 brokers have issued 12-month price objectives for Aethlon Medical's stock. Their AEMD share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 2,117.8% from the stock's current price. View analysts price targets for AEMD or view top-rated stocks among Wall Street analysts. How have AEMD shares performed in 2024? Aethlon Medical's stock was trading at $2.19 at the start of the year. Since then, AEMD shares have decreased by 79.4% and is now trading at $0.4509. View the best growth stocks for 2024 here. When is Aethlon Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024. View our AEMD earnings forecast. How were Aethlon Medical's earnings last quarter? Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings results on Thursday, August, 10th. The medical equipment provider reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.10. During the same period in the prior year, the firm earned ($1.90) earnings per share. When did Aethlon Medical's stock split? Aethlon Medical shares reverse split on Thursday, October 5th 2023. The 1-10 reverse split was announced on Wednesday, October 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Aethlon Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia Oyj (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), Organigram (OGI), AT&T (T) and Who are Aethlon Medical's major shareholders? Aethlon Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Aethlon Medical? Shares of AEMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AEMD) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden FINISHED On June 13th?Paradigm PressDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trendsis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aethlon Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
